Obstetrics & Gynecology Track the topics, authors and articles important to you
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Obstetrics & Gynecology 1983;62:231-235
© 1983 by The American College of Obstetricians and Gynecologists
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by HOLT, J. A.
Right arrow Articles by KING, W. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by HOLT, J. A.
Right arrow Articles by KING, W. J.

Antibody-Recognized [125I]Estradiol—Receptor Complex in Ovarian Epithelial Carcinoma

JOHN A. HOLT, PhD, MARGARET A. LORINCZ, MS and WILLIAM J. KING, PhD

From the Department of Obstetrics and Gynecology and the Ben May Laboratory for Cancer Research, The University of Chicago, Chicago, Illinois

Abstract

Monoclonal antibody against human breast cancer estrogen receptor was used to demonstrate binding of a gamma- and Auger electron-emitting estrogen to the estrogen receptor in ovarian epithelial carcinomas. When cytosols of estrogen receptor-rich ovarian adenocarcinomas were analyzed on sucrose gradients containing 0.4 M KCl, the presence of monoclonal antibody against breast cancer estrogen receptor caused a binding peak for [125I]- and [3H]estradiol to shift from the 4S to the 8-9S region, indicating antibody complex formation with ovarian adenocarcinoma estrogen receptor. The antibody-shifted peak of 8-9S [125I]- and [3H]estradiol binding was totally inhibited by a 100-fold molar excess of diethylstilbestrol (DES), but not by testosterone or progesterone, indicating a preference for estrogen binding by the antibody-shifted estrogen receptor. When estrogen receptor from the nuclear fraction of ovarian adenocarcinomas was incubated with [125I]estradiol at 1C, in the presence of 0.4 M NaSCN to facilitate exchange with endogenous ligand, binding occurred that was inhibitable by DES and restricted to the 4S region. Under these conditions the nuclear estrogen receptor was also shifted to the 8-9S region by the presence of the monoclonal antibody against estrogen receptor.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1983 by the American College of Obstetricians and Gynecologists.